Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.58 |
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.46 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269690 | 1.00 | USP30 (0.58) | USP30PARP1HDAC4HDAC6ANO1 | |
| SCHEMBL268538 | 1.00 | USP30 (0.58) | USP30PARP1HDAC4HDAC6ANO1 | |
| SCHEMBL7243205 | 0.85 | USP30 (0.52) | USP30PARP1HDAC4HDAC6ANO1 | |
| SCHEMBL16334671 | 0.81 | USP30 (0.65) | USP30PARP1HDAC4HDAC6PBK | |
| SCHEMBL10224520 | 0.81 | USP30 (0.65) | USP30PARP1HDAC4HDAC6PBK | |
| SCHEMBL1674871 | 0.81 | USP30 (0.65) | USP30PARP1HDAC4HDAC6PBK | |
| SCHEMBL269564 | 0.78 | GAA (0.50) | USP30MEN1KMT2A | |
| SCHEMBL5145035 | 0.77 | USP30 (0.82) | USP30PARP1HDAC4HDAC6ANO1 | |
| SCHEMBL29136117 | 0.75 | USP30 (0.78) | USP30PARP1HDAC4HDAC6ANO1 | |
| SCHEMBL30089220 | 0.75 | USP30 (0.78) | USP30PARP1HDAC4HDAC6ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2094685-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008065626-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVESAS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | USP30 3229/4885PARP1 2657/4885HDAC4 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.